Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book

IJ Pharmaceutical Research

homeHome
play_arrowCurrent Issueformat_list_bulletedAll Issuesformat_indent_increaseIn Presscheck_boxAccepted Manuscripts
searchSearchqr_codeInstructions
bookmarkJournal InformationgroupsEditors & BoardsshareIndexing and Listing Sourceswaterfall_chartJournal Metricszoom_inOpen Peer Review (OPR)balancePublication Ethics and Malpractice Statementassignment_indReviewer and AE Registration FormemailSupportphoneContact Us
menuAPC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)

1. Budget impact analysis of glecaprevir/pibrentasvir treatment for hepatitis C in Iran: a modelling study

- Jafari M. , et al.

2. Balancing innovation and affordability in relapsing-remitting multiple sclerosis: a budget impact analysis from Saudi Arabia

- Al-Jedai A. , et al.

3. The Lebanese health economic evaluation guideline

- Daccache C. , et al.

4. Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea

- Shih Y.R. , et al.

5. Study on the Medical Insurance Budget Impact Analysis Guideline in Some European Countries and Its Enlightenment to China

- Liu P. , et al.

6. A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions

- Foroutan N. , et al.

7. Administrative process and criteria ranking for drug entering health insurance list in Iran-TOPSIS-based consensus model

- Viyanchi A. , et al.

8. Budget impact analysis of using omeprazole immediate-release oral suspension in replace of intravenous pantoprazole in critically ILL patients

- Foroutan N. , et al.